Peter Kälebo

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial

Bengt I. Eriksson, O.E. Dahl, Nadia Rosencher et al. · Journal of Thrombosis and Haemostasis · 2007 · 984 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +15

A Comparison of Recombinant Hirudin with a Low-Molecular-Weight Heparin to Prevent Thromboembolic Complications after Total Hip Replacement

Bengt I. Eriksson, Peter Kälebo, Patrick Mouret et al. · New England Journal of Medicine · 1997 · 371 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +17

A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement

Bengt I. Eriksson, Lars C. Borris, Ola E. Dahl et al. · Circulation · 2006 · 332 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

Alexander G.G. Turpie, W. D. Fisher, Kenneth A. Bauer et al. · Journal of Thrombosis and Haemostasis · 2005 · 301 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +14

Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement

Bengt I. Eriksson, Lars C. Borris, O.E. Dahl et al. · Journal of Thrombosis and Haemostasis · 2005 · 300 citations · Full text

Medicine, Orthopedic Surgery, Pharmacology +17